Human parainfluenza virus type 3 fusion protein (HPIV3 F protein)

The **human parainfluenza virus type 3 fusion protein (F protein)** is a type I integral membrane glycoprotein embedded in the viral envelope. It functions as a homotrimer and mediates fusion between the viral envelope and the host cell membrane, a critical step for viral entry and infectivity[9][7]. The F protein is synthesized as a precursor (F0) that requires cleavage by host cell proteases, notably TMPRSS2 and TMPRSS13, to become fusogenic[5]. Its conformational changes, triggered after receptor engagement by the hemagglutinin-neuraminidase (HN) protein, drive the merger of viral and cellular membranes, releasing the viral genome into the host cytoplasm[7][9]. The HPIV3 F protein is also a major antigenic target for neutralizing antibodies, making it an important focus for immunotherapeutics and vaccine development[7]. Structural and genetic variations in the F protein affect susceptibility to neutralization by antibodies and may play a role in immune escape[6][9]. Presently, there are no approved drugs specifically targeting the HPIV3 F protein, but investigational monoclonal antibodies and fusion inhibitors are in development, and targeting F protein-mediated fusion remains a major antiviral strategy[7][9].

Other names

Fusion protein (F protein)HPIV3 F proteinhPIV3 F protein

*Monoclonal antibodies*: Block conformational changes in F protein, prevent fusion of viral and cell membranes, and thus block viral entry[7] *Fusion inhibitors*: Interfere with the formation of the six-helix bundle necessary for membrane fusion *Protease inhibitors*: Block cleavage activation of precursor F0 to fusogenic F1, inhibiting fusion[5]